Literature DB >> 31810790

Stem, Effector, and Hybrid States of Memory CD8+ T Cells.

Enrico Lugli1, Giovanni Galletti2, Shannon K Boi3, Benjamin A Youngblood4.   

Abstract

CD8+ T cell immunological memory of past antigen exposure can confer long-lived protection against infections or tumors. The fact that CD8+ memory T cells can have features of both naïve and effector cells has forced the field to struggle with several conceptual questions about the developmental origin of the cell and, consequently, the mechanism(s) that contribute to memory development. Here, we discuss recent conceptual advances in our understanding of memory T cell development that incorporate data describing a hybrid stem and/or effector state of differentiation. We theorize that the mechanisms involved in developing these cells could be mediated, in part, through epigenetic programs. Finally, we consider the potential therapeutic implications of inducing and/or utilizing such hybrid cells clinically.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD8+ T cells; TCF1; cancer immunotherapy; effector; exhaustion; memory; naïve

Mesh:

Substances:

Year:  2019        PMID: 31810790      PMCID: PMC6934921          DOI: 10.1016/j.it.2019.11.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  89 in total

1.  Preferential localization of effector memory cells in nonlymphoid tissue.

Authors:  D Masopust; V Vezys; A L Marzo; L Lefrançois
Journal:  Science       Date:  2001-03-01       Impact factor: 47.728

2.  The epigenetic control of stemness in CD8+ T cell fate commitment.

Authors:  Luigia Pace; Christel Goudot; Elina Zueva; Paul Gueguen; Nina Burgdorf; Joshua J Waterfall; Jean-Pierre Quivy; Geneviève Almouzni; Sebastian Amigorena
Journal:  Science       Date:  2018-01-12       Impact factor: 47.728

3.  The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness.

Authors:  Tuoqi Wu; Yun Ji; E Ashley Moseman; Haifeng C Xu; Monica Manglani; Martha Kirby; Stacie M Anderson; Robin Handon; Elizabeth Kenyon; Abdel Elkahloun; Weiwei Wu; Philipp A Lang; Luca Gattinoni; Dorian B McGavern; Pamela L Schwartzberg
Journal:  Sci Immunol       Date:  2016-12-09

4.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Douglas C Palmer; Claudia Wrzesinski; Keith Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

5.  Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.

Authors:  Kristen E Pauken; Morgan A Sammons; Pamela M Odorizzi; Sasikanth Manne; Jernej Godec; Omar Khan; Adam M Drake; Zeyu Chen; Debattama R Sen; Makoto Kurachi; R Anthony Barnitz; Caroline Bartman; Bertram Bengsch; Alexander C Huang; Jason M Schenkel; Golnaz Vahedi; W Nicholas Haining; Shelley L Berger; E John Wherry
Journal:  Science       Date:  2016-10-27       Impact factor: 47.728

6.  Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8+ T Cell Terminal Differentiation and Loss of Multipotency.

Authors:  Simon M Gray; Robert A Amezquita; Tianxia Guan; Steven H Kleinstein; Susan M Kaech
Journal:  Immunity       Date:  2017-04-11       Impact factor: 31.745

7.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Authors:  Se Jin Im; Masao Hashimoto; Michael Y Gerner; Junghwa Lee; Haydn T Kissick; Matheus C Burger; Qiang Shan; J Scott Hale; Judong Lee; Tahseen H Nasti; Arlene H Sharpe; Gordon J Freeman; Ronald N Germain; Helder I Nakaya; Hai-Hui Xue; Rafi Ahmed
Journal:  Nature       Date:  2016-08-02       Impact factor: 49.962

8.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

9.  High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors.

Authors:  Jolanda Brummelman; Emilia M C Mazza; Giorgia Alvisi; Federico S Colombo; Andrea Grilli; Joanna Mikulak; Domenico Mavilio; Marco Alloisio; Francesco Ferrari; Egesta Lopci; Pierluigi Novellis; Giulia Veronesi; Enrico Lugli
Journal:  J Exp Med       Date:  2018-08-28       Impact factor: 14.307

10.  Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity.

Authors:  Shan He; Yongnian Liu; Lijun Meng; Hongxing Sun; Ying Wang; Yun Ji; Janaki Purushe; Pan Chen; Changhong Li; Jozef Madzo; Jean-Pierre Issa; Jonathan Soboloff; Ran Reshef; Bethany Moore; Luca Gattinoni; Yi Zhang
Journal:  Nat Commun       Date:  2017-12-14       Impact factor: 14.919

View more
  22 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

2.  Reference range of naïve T and T memory lymphocyte subsets in peripheral blood of healthy adult.

Authors:  Ying Xia; Aqing Liu; Wentao Li; Yunhe Liu; Guan Zhang; Songshan Ye; Zhijieruo Zhao; Juan Shi; Yingjie Jia; Xu Liu; Yongtie Guo; Huayu Chen; Jianchun Yu
Journal:  Clin Exp Immunol       Date:  2022-04-04       Impact factor: 4.330

3.  cBAF complex components and MYC cooperate early in CD8+ T cell fate.

Authors:  Ao Guo; Hongling Huang; Zhexin Zhu; Mark J Chen; Hao Shi; Sujing Yuan; Piyush Sharma; Jon P Connelly; Swantje Liedmann; Yogesh Dhungana; Zhenrui Li; Dalia Haydar; Mao Yang; Helen Beere; Jason T Yustein; Christopher DeRenzo; Shondra M Pruett-Miller; Jeremy Chase Crawford; Giedre Krenciute; Charles W M Roberts; Hongbo Chi; Douglas R Green
Journal:  Nature       Date:  2022-06-22       Impact factor: 69.504

Review 4.  'Stem-like' precursors are the fount to sustain persistent CD8+ T cell responses.

Authors:  Dietmar Zehn; Robert Thimme; Enrico Lugli; Gustavo Pereira de Almeida; Annette Oxenius
Journal:  Nat Immunol       Date:  2022-05-27       Impact factor: 31.250

Review 5.  Phenotypic and Immunometabolic Aspects on Stem Cell Memory and Resident Memory CD8+ T Cells.

Authors:  Marco Pio La Manna; Mojtaba Shekarkar Azgomi; Bartolo Tamburini; Giusto Davide Badami; Leila Mohammadnezhad; Francesco Dieli; Nadia Caccamo
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

Review 6.  Regulation of activated T cell survival in rheumatic autoimmune diseases.

Authors:  Florencia Rosetti; Iris K Madera-Salcedo; Noé Rodríguez-Rodríguez; José C Crispín
Journal:  Nat Rev Rheumatol       Date:  2022-01-24       Impact factor: 32.286

7.  Early precursor T cells establish and propagate T cell exhaustion in chronic infection.

Authors:  Daniel T Utzschneider; Sarah S Gabriel; David Chisanga; Renee Gloury; Patrick M Gubser; Ajithkumar Vasanthakumar; Wei Shi; Axel Kallies
Journal:  Nat Immunol       Date:  2020-08-24       Impact factor: 25.606

Review 8.  New developments implicating IL-21 in autoimmune disease.

Authors:  Heather M Ren; Aron E Lukacher; Ziaur S M Rahman; Nancy J Olsen
Journal:  J Autoimmun       Date:  2021-07-02       Impact factor: 14.511

Review 9.  Genome-edited adult stem cells: Next-generation advanced therapy medicinal products.

Authors:  Karim Benabdellah; Sabina Sánchez-Hernández; Araceli Aguilar-González; Noelia Maldonado-Pérez; Alejandra Gutierrez-Guerrero; Marina Cortijo-Gutierrez; Iris Ramos-Hernández; María Tristán-Manzano; Pablo Galindo-Moreno; Concha Herrera; Francisco Martin
Journal:  Stem Cells Transl Med       Date:  2020-03-06       Impact factor: 6.940

10.  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.

Authors:  Anna Dalla Pietà; Elisa Cappuzzello; Roberta Sommaggio; Antonio Rosato; Pierangela Palmerini; Annavera Ventura; Andrea Visentin; Giuseppe Astori; Katia Chieregato; Valentina Mozzo; Omar Perbellini; Maria Chiara Tisi; Livio Trentin; Carlo Visco; Marco Ruggeri
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.